The intense bioethics debate surrounding "designer babies" has officially left the realm of science fiction and entered the commercial medical marketplace. A new generation of advanced IVF startups is utilizing polygenic risk scoring (PRS) to analyze human embryos during in vitro fertilization. These companies claim they can screen, score, and rank embryos not merely for inherited monogenic disorders like cystic fibrosis, but for complex polygenic traits, including predicted lifespan potential, susceptibility to chronic diseases, and even cognitive capabilities.
It is being marketed to prospective parents as the ultimate expression of parental love: utilizing cutting-edge genomic data to insulate your future child from disease while maximizing their natural intellectual and physical head start. However, beneath this polished promise of preventative medicine lies a profound ethical, moral, and sociological minefield.
The Shift from Acceptance to Engineering
The most immediate psychological dilemma of embryo ranking is the fundamental restructuring of parenthood. Historically, parenthood has been built on a foundation of unconditional acceptance, welcoming a child into the world regardless of their biological quirks.
When parents begin selecting an embryo based on a comparative spreadsheet score for IQ or longevity, the dynamic shifts from a relationship of unconditional love to a relationship of consumer optimization. The child risks being viewed not as an individual human being, but as a product engineered to meet specific lifestyle and performance benchmarks.
The Threat of a Genetic Divide
Beyond the household, the societal implications of this technology are deeply unsettling.
Polygenic embryo screening is a highly expensive elective medical procedure. If this technology remains unregulated and accessible only to affluent families, we risk moving past standard economic inequality into a dystopian reality of biological inequality.
If a wealthy segment of the population can systematically select for extended lifespans, lower disease profiles, and enhanced cognitive traits over multiple generations, society will face a deep, permanent genetic divide. While optimizing our personal daily wellness via sleep, diet, and exercise is a universal pursuit, attempting to pre-program human potential prior to birth challenges the very definition of human equality.
References
Grokipedia, 2026. Herasight: biotechnology, polygenic genomic screening, and embryology analytics. [online] Available at: https://grokipedia.com/page/herasight
Karavani, E., Zuk, O., Zeevi, D., Kim, N., Lavrik, M., Petruso, O., Lencz, T. and Carmi, S., 2019. Screening human embryos for polygenic traits has limited utility. Cell, 179(7), pp.1424-1435.
Lencz, T., Sabatello, M., Green, R., Applebaum, P. and Carmi, S., 2022. Preimplantation genetic testing for polygenic traits (PGT-P): ethical, legal, and social implications. Report of the International Society of Psychiatric Genetics, 32(5), pp.512-525.
Turley, P., Meyer, M.N., Wang, N., Cesarini, D., Hammonds, E., Martin, A.R., Meyer, M.N., Neale, B.M., Visco, R. and Benjamin, D.J., 2021. Problems with using polygenic scores to select embryos and alternate clinical pathways. New England Journal of Medicine, 385(1), pp.78-86.
